Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
DVAX's Cash-to-Debt is ranked higher than
96% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. DVAX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
DVAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.34  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.93
DVAX's Equity-to-Asset is ranked higher than
93% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DVAX: 0.93 )
Ranked among companies with meaningful Equity-to-Asset only.
DVAX' s Equity-to-Asset Range Over the Past 10 Years
Min: -2.28  Med: 0.76 Max: 0.93
Current: 0.93
-2.28
0.93
Interest Coverage No Debt
DVAX's Interest Coverage is ranked higher than
96% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. DVAX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
DVAX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 60.37
Beneish M-Score: -2.60
WACC vs ROIC
5.63%
-1566.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1296.64
DVAX's Operating Margin % is ranked lower than
79% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. DVAX: -1296.64 )
Ranked among companies with meaningful Operating Margin % only.
DVAX' s Operating Margin % Range Over the Past 10 Years
Min: -2594.4  Med: -547.7 Max: -37.49
Current: -1296.64
-2594.4
-37.49
Net Margin % -1323.99
DVAX's Net Margin % is ranked lower than
80% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. DVAX: -1323.99 )
Ranked among companies with meaningful Net Margin % only.
DVAX' s Net Margin % Range Over the Past 10 Years
Min: -2636.89  Med: -509.28 Max: -56.15
Current: -1323.99
-2636.89
-56.15
ROE % -88.86
DVAX's ROE % is ranked lower than
73% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. DVAX: -88.86 )
Ranked among companies with meaningful ROE % only.
DVAX' s ROE % Range Over the Past 10 Years
Min: -307.22  Med: -77.84 Max: -49.94
Current: -88.86
-307.22
-49.94
ROA % -75.17
DVAX's ROA % is ranked lower than
77% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. DVAX: -75.17 )
Ranked among companies with meaningful ROA % only.
DVAX' s ROA % Range Over the Past 10 Years
Min: -85.08  Med: -52 Max: -19.74
Current: -75.17
-85.08
-19.74
ROC (Joel Greenblatt) % -586.02
DVAX's ROC (Joel Greenblatt) % is ranked lower than
54% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. DVAX: -586.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
DVAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1090.64  Med: -785.29 Max: -172.67
Current: -586.02
-1090.64
-172.67
3-Year Revenue Growth Rate -20.60
DVAX's 3-Year Revenue Growth Rate is ranked lower than
72% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. DVAX: -20.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
DVAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.4 Max: 88.2
Current: -20.6
0
88.2
3-Year EBITDA Growth Rate -4.80
DVAX's 3-Year EBITDA Growth Rate is ranked lower than
59% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. DVAX: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
DVAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -63.3  Med: -11.5 Max: 39.1
Current: -4.8
-63.3
39.1
3-Year EPS without NRI Growth Rate -8.60
DVAX's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. DVAX: -8.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
DVAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -60.6  Med: -18.2 Max: 26.3
Current: -8.6
-60.6
26.3
GuruFocus has detected 5 Warning Signs with Dynavax Technologies Corp $DVAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» DVAX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

DVAX Guru Trades in Q3 2016

Paul Tudor Jones 22,654 sh (New)
Steven Cohen 1,754,000 sh (+289.48%)
John Paulson 174,000 sh (unchged)
Chuck Royce 120,000 sh (-26.83%)
» More
Q4 2016

DVAX Guru Trades in Q4 2016

Jim Simons 463,951 sh (New)
Paul Tudor Jones 63,600 sh (+180.75%)
John Paulson 174,000 sh (unchged)
Steven Cohen Sold Out
Chuck Royce 111,000 sh (-7.50%)
» More
Q1 2017

DVAX Guru Trades in Q1 2017

Steven Cohen 726,500 sh (New)
John Paulson 463,000 sh (+166.09%)
Jim Simons 574,051 sh (+23.73%)
Chuck Royce Sold Out
Paul Tudor Jones Sold Out
» More
Q2 2017

DVAX Guru Trades in Q2 2017

Steven Cohen 1,361,100 sh (+87.35%)
John Paulson 554,600 sh (+19.78%)
Steven Cohen 600,000 sh (unchged)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DVAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-06-30 Add 19.78%0.01%$5.15 - $10.35 $ 22.30245%554,600
John Paulson 2017-03-31 Add 166.09%0.02%$3.8 - $6.9 $ 22.30364%463,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:GBT, NAS:AIMT, SZSE:000403, NAS:LXRX, SHSE:603718, XSWX:SFZN, NYSE:CO, SZSE:300255, NAS:ESPR, XTER:BIO3, SZSE:002022, TSE:4565, NAS:SGMO, NAS:ASND, NYSE:BHVN, SZSE:000518, OCSE:BAVA, SZSE:300204, XKRX:005250, NAS:ZLAB » details
Traded in other countries:DYF1.Germany,
Headquarter Location:USA
Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor ("TLR") stimulation.

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment: the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

Top Ranked Articles about Dynavax Technologies Corp

Analysts Take Action on Health Care Stocks AbbVie downgraded to Neutral, and Quest Diagnostics reduced to Market Perform
Recently analysts have released their new ratings on health care stocks. Read more...
Dynavax Technologies Skyrockets on Hepatitis B Vaccine The stock almost doubles on FDA safety approval
Wall Street is trading slightly in the green with the three indexes up around 0.2%. Among today's gainers, Dynavax Technologies Corp. (NASDAQ:DVAX) is in the spotlight. Read more...
What Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA A look at the upcoming PDUFA decision, what's come before it and some things to consider for those holding or thinking about picking up an exposure
There is a large unmet need right now in the hepatitis B space. A recent study has revealed only half of the individuals that receive hepatitis B vaccinations are actually gaining any sort of immunity to the virus. Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.68
DVAX's PB Ratio is ranked lower than
77% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. DVAX: 8.68 )
Ranked among companies with meaningful PB Ratio only.
DVAX' s PB Ratio Range Over the Past 10 Years
Min: 0.65  Med: 4.46 Max: 14.94
Current: 8.68
0.65
14.94
PS Ratio 112.07
DVAX's PS Ratio is ranked lower than
85% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. DVAX: 112.07 )
Ranked among companies with meaningful PS Ratio only.
DVAX' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 24.24 Max: 208.92
Current: 112.07
0.18
208.92
EV-to-EBIT -12.03
DVAX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. DVAX: -12.03 )
Ranked among companies with meaningful EV-to-EBIT only.
DVAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.2  Med: -3.3 Max: 6.3
Current: -12.03
-26.2
6.3
EV-to-EBITDA -12.37
DVAX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. DVAX: -12.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
DVAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.3  Med: -3.3 Max: 32.5
Current: -12.37
-16.3
32.5
EV-to-Revenue 158.58
DVAX's EV-to-Revenue is ranked lower than
84% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. DVAX: 158.58 )
Ranked among companies with meaningful EV-to-Revenue only.
DVAX' s EV-to-Revenue Range Over the Past 10 Years
Min: -1.6  Med: 18.5 Max: 172.1
Current: 158.58
-1.6
172.1
Current Ratio 11.92
DVAX's Current Ratio is ranked higher than
84% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. DVAX: 11.92 )
Ranked among companies with meaningful Current Ratio only.
DVAX' s Current Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.97 Max: 13.98
Current: 11.92
1.87
13.98
Quick Ratio 11.92
DVAX's Quick Ratio is ranked higher than
84% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. DVAX: 11.92 )
Ranked among companies with meaningful Quick Ratio only.
DVAX' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.97 Max: 13.98
Current: 11.92
1.87
13.98
Days Sales Outstanding 38.36
DVAX's Days Sales Outstanding is ranked higher than
74% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. DVAX: 38.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
DVAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.1  Med: 48.57 Max: 187.36
Current: 38.36
8.1
187.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -13.70
DVAX's 3-Year Average Share Buyback Ratio is ranked lower than
52% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. DVAX: -13.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
DVAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -180.4  Med: -29.8 Max: -9.4
Current: -13.7
-180.4
-9.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.57
DVAX's Price-to-Net-Cash is ranked lower than
60% of the 543 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. DVAX: 10.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
DVAX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.85  Med: 5.12 Max: 26.38
Current: 10.57
1.85
26.38
Price-to-Net-Current-Asset-Value 10.09
DVAX's Price-to-Net-Current-Asset-Value is ranked lower than
62% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. DVAX: 10.09 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DVAX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.79  Med: 4.67 Max: 124
Current: 10.09
1.79
124
Price-to-Tangible-Book 8.81
DVAX's Price-to-Tangible-Book is ranked lower than
68% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. DVAX: 8.81 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
DVAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.73  Med: 4.11 Max: 27.68
Current: 8.81
1.73
27.68
Price-to-Median-PS-Value 4.63
DVAX's Price-to-Median-PS-Value is ranked lower than
92% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. DVAX: 4.63 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
DVAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.02  Med: 0.82 Max: 7.67
Current: 4.63
0.02
7.67
Earnings Yield (Greenblatt) % -8.31
DVAX's Earnings Yield (Greenblatt) % is ranked lower than
53% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. DVAX: -8.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
DVAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -14882  Med: -25.7 Max: 3563.3
Current: -8.31
-14882
3563.3

More Statistics

Revenue (TTM) (Mil) $7.71
EPS (TTM) $ -2.47
Beta0.55
Short Percentage of Float13.63%
52-Week Range $3.20 - 24.45
Shares Outstanding (Mil)60.50

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -1.69 -1.65
EPS without NRI ($) -1.69 -1.65
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}